METHODS: A retrospective cohort study was performed to examine whether higher statin adherence level, measured as medication possession ratio (MPR), is associated with lower health care costs and hospital admission rate and with fewer ER visits. The study sample consisted of adult patients aged 18-64 years on an index date with continuous enrollment 12 months prior to and 12 months after the index date (the first fill date of a statin between January 1, 2009, and December 31, 2010). Study subjects also needed to have a minimum of 2 ICD-9-CM diagnoses for hyperlipidemia or diabetes in the pre-index date period. Main data sources were medical and prescription (Rx) claims, as well as enrollment files provided by a health benefit program and a medical carrier of state government and public school employees in a midwestern state. Study subjects were stratified into 8 groups based on statin MPR level: < 40%, 40%-59%, 60%-69%, 70%-79%, 80%-84%, 85%-89%, 90%-95%, and 96%-100%. Total medical and Rx costs, as well as all-cause hospital admission rates and ER visits in a year after the index date, were computed based on medical and Rx claims. A separate breakout of statin costs, part of total Rx costs, was also computed. Generalized linear models (GLMs) were developed to test the hypothesis that higher statin adherence levels are associated with lower health care costs and utilization.
RESULTS: A total of 10,312 subjects met the criteria and were selected. The average statin MPR in a year after the index date was 71.95%. Mean total costs (medical + Rx) in a year after the index date were $6,064.36. There were significant variations in Rx costs and total health care costs as well as ER visits among the 8 patient groups stratified using the statin MPR level. A GLM model showed that all the ratios of health care costs among groups with statin MPR from 40%-59%, 60%-69%, 80%-84%, 85%-89%, 90%-95%, and 96%-100% were larger than 1 and statistically significant compared with the reference group with statin MPR <40%, suggesting those groups had higher health care costs than the reference group with the lowest statin MPR level. Based on a logistic regression model of hospital utilization for this study population, all the odds ratios of all-cause hospitalization among the groups with higher statin MPR were not statistically significant, suggesting that the likelihood of hospitalization for patients with higher statin MPR was not statistically lower than that of the reference group with statin MPR<40%. After controlling for all other covariates, another GLM model based on the Poisson distribution and log link function showed that ratios of ER visits among groups with statin MPR from 60%-69%, 80%-84%, 85%-89%, 90%-95%, and 96%-100% were smaller than 1 and statistically significant, suggesting the groups had fewer ER visits than the reference group with statin MPR < 40%. The patient group with statin MPR from 96%-100% was estimated to have the lowest number of ER visits.
• Clinical benefits of statin therapy have been well documented.
• A large proportion of patients prescribed statins do not take medications as directed by their prescribers.
• Nonadherence to statins is strongly associated with poor treatment outcomes.
• It is not clear whether increasing statin adherence level can bring about better clinical outcomes, which may be translated into cost savings and lower health care utilization.
• Evidence about associations between statin adherence level, total health care costs, and medical utilization is still limited.
What is already known about this subject
• Significant variations in total health care costs and emergency room (ER) visits were shown among the 8 patient groups with different statin medication possession ratio (MPR) levels.
• Most of the patient groups with statin MPR higher than 60% had fewer ER visits than the reference group with statin MPR < 40%. The patient group with highest statin MPR had the fewest ER visits. • Higher statin adherence level is related to fewer ER visits among beneficiaries after statin treatment is taken for a year. However, our study does not suggest higher statin adherence levels are associated with directly measureable lower overall health care costs within 1 year after statin therapy is taken.
with a total cholesterol of 200 and a high-density lipoprotein of 45, who is normotensive, does not have diabetes, and is not a smoker, has a 10-year ASCVD risk of 5.5. An African American with the same attributes has a risk of 6.1, about 11% higher. The risk for the same patients with diabetes increases to 10.3 and 11.4, respectively. Similarly, if both patients were not diabetic but were smokers, their risks would be 10.2 and 10.4. For comparison, if these patients were both smokers and had diabetes, their ASCVD risks would be 18.7 and 18.9, respectively. Statin adherence is still a major issue among patients on the treatment. Other studies indicate that a large proportion of patients prescribed statins do not take their medicine on a regular basis. 9 Studies also show nonadherence to statin therapy is strongly associated with poor treatment outcomes. 10 Although the working population may have a relatively high adherence rate, a reason to focus on improving adherence further in the group who has not retired is the addition of smokers to those fitting the guidelines for statin therapy. As previously indicated, smoking increases the ASCVD risk from 5.5 (white) or 6.1 (African American) to 10.2 and 10.4, respectively, for an average man in our study population. Poor adherence to statin therapy is also associated with significantly higher risk of cardiovascular mortality. 11 Higher statin adherence levels may achieve better reductions in lipid levels in a year after statin therapy is taken. 12 Whether increasing statin adherence levels can bring about better clinical outcomes is unclear, however. If better outcomes are possible, they may be translated into cost savings and lower overall health care utilization in a year after starting statin therapy.
Few previous studies examined the associations between statin adherence level, health care costs, and utilization (especially emergency room [ER] visits). One cohort study with about 3,000 patients from a large employer-sponsored health plan evaluated the impact of statin adherence levels on health care costs and hospitalization among patients with hypercholesterolemia. Study subjects were stratified into 5 groups based on the quintiles of statin adherence level, which was measured as the percentage of days supplied during a 12-month period after patients had index medical claims from 1997-1999. The results showed patients with adherence levels higher than 80% had lower health care costs and hospital admission rates than other groups with lower adherence levels. 13 Another cohort study examined relationships between statin adherence, health care costs, and cardiovascular hospitalizations. The results indicated that the group with medication possession ratio (MPR) from 90%-100% had the lowest total costs and cardiovascular-related hospitalizations in the subsequent 18 months after the index date, compared with other MPR groups. 14 Gleason et al. (2012) performed a study assessing associations between statin adherence, hospitalization, ER visits, and total costs over 2 years after the index date, which was defined as the date of the first diagnosis of hyperlipidemia in 2008. 15 The goals of reducing all-cause mortality and major cardiovascular events, including myocardial infarction and stroke. [2] [3] [4] Patients with cardiovascular diseases may also achieve secondary prevention goals from statin therapy. Previous studies found that statin treatment was associated with lower all-cause mortality, cardiovascular mortality, revascularization procedures, myocardial infarction, and stroke among patients with coronary heart disease. 5 Previous treatment guidelines recommended statin therapy in patients with various cardiovascular risks to prevent or reduce the occurrence of future cardiovascular events. 6, 7 However, new guidelines recently published by the American College of Cardiology and the American Heart Association (ACC/AHA) expand the recommendation for statin therapy to include patients with an atherosclerotic cardiovascular disease (ASCVD) risk score of ≥ 7.5% (the percentage risk of a heart attack or stroke within the next 10 years). 8 The new guidelines not only address an individual's risk of heart attack but also include, for the first time, the risk of stroke. These conditions represent the number 1 and 4 causes of death in the United States, so compliance with recommended therapies, including adherence to statin therapy, can have a major impact on related morbidity and mortality.
The new guidelines emphasize adherence to the following lifestyle recommendations, both before statin therapy thresholds are reached and in concert with appropriate statin therapy: (a) adhere to a heart-healthy diet, (b) exercise regularly, (c) avoid tobacco products, (d) maintain a healthy weight. The new guidelines go on to recommend statin therapy for individuals meeting 1 or more of the following:
• People without cardiovascular disease who are 40 to 75 years of age and have a 7.5% or higher risk for heart attack or stroke within 10 years.
• People with a history of heart attack, stroke, stable or unstable angina, peripheral artery disease, transient ischemic attack, or coronary or other arterial revascularization.
• People 21 and older who have a very high level of bad cholesterol (≥ 190 milligrams per deciliter).
• People with type 1 or type 2 diabetes who are 40 to 75 years old. 8 To complement the ACC/AHA guidelines, those organizations also published the "Omnibus Risk Estimator," an ASCVD risk calculator that, for the first time, reflects separate risk calculations for African Americans and also includes stroke. The factors considered in the risk calculator include the following: gender, age, race (African American or white), total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for high blood pressure, diabetes, and smoking.
The implications of the new ACC/AHA guidelines could be a significant increase in the number of people who meet the thresholds for statin therapy. For example, a white male 55 years of age (about the average age of subjects in our study), study cohort included adult patients who were diagnosed as hyperlipidemic in 2008 or with high risk conditions such as diabetes, coronary artery disease, embolic stroke, or peripheral vascular disease prior to 2008. Generalized linear models (GLMs) showed that patients with statin adherence defined as proportion of days covered ≥ 80% had higher total costs but lower hospital admission rates and ER visits in the 2-year period, when compared with nonadherent patients. 15 Evidence of associations between statin adherence level, health care costs, and utilization is still limited. Because of ethical issues, no randomized controlled trials were performed to evaluate the impact of statin adherence level on total medical and prescription (Rx) costs or on health care utilization. Available observational studies did not offer sufficient evidence about the impact of statin adherence level on health care utilization and costs, especially the impact of statin adherence levels > 80%, the threshold commonly used to define medication adherence. 16, 17 More research is needed to further examine whether higher statin adherence levels are associated with cost savings and lower health care utilization. The objectives of this study were to evaluate the associations between statin adherence level, overall health care costs, hospital admission rates, and ER visits in a year after statin therapy is started.
■■ Methods Study Sample and Data Sources
A retrospective cohort study was performed to pursue the study objectives, which were to evaluate whether adherence level to statins is associated with health care costs and utilization. The study subjects consisted of more than 200,000 state government and public school employees and beneficiaries enrolled in a health plan in a midwestern state. The subjects were adult patients aged 18 to 64 years on the index date, the first filling date of statin from 2009-2010, who had at least 2 fills of statin medications in a year after the index date and who enrolled for 12 months before and after the index date. The study sample may contain patients who were naÏve to statin therapy and patients who were on statin treatment for some time. To reduce problems with coding issues in health insurance claims data, patients who did not have at least 2 hyperlipidemia or diabetes diagnoses identified from medical claims data in the year prior to the index date were also excluded from the study. Patients with the presence of a medical claim diagnosis of cancer during the 12 months prior to the index date were excluded. In addition, patients with diagnoses of trauma in a year after the index date were excluded. The study sample selection criteria are illustrated in Figure 1 .
Main data sources of this study included paid administrative medical claims, which a health benefit program and medical carrier of state government and public school employees provided, as well as eligibility files and Rx claims data from 2008-2011, which were collected and administered by a leading pharmacy benefit manager. Another data source was U.S.
Census 2010 data, which was used to generate variables related to patients' residential area characteristics.
Outcome Measures
Total medical, Rx, and statin costs and all-cause hospital admission and ER visits in the 12 months after the index date were computed based on medical and Rx claims. All costs were calculated based on the allowed amount. All-cause hospital admissions and ER visits were identified based on the place of service codes in medical claims in a year after the index date.
Study Variables
Statin adherence level was measured as MPR in the 12-month period after the index date based on the notion that clinical benefits from statin treatment may occur after 1-2 years of therapy. 18 Statin medications were identified using National Drug Code numbers in Rx claims data. Covariates affecting both statin adherence level and health care utilization and costs were also generated from medical claims and other data sources. Age and gender were collected from enrollment files of study subjects. Average copayment per Rx fill was computed based on Rx claims in the 12-month period after the index date, with the first date of statin Rx fill between 2009-2010. Variables indicating whether a patient lived in a metropolitan statistical area with more than 50,000 residents, a micropolitan statistical area with a population between 10,000 and 50,000, or a rural area with less than 10,000 residents were generated from U.S. Census 2010 data based on patients' residence ZIP codes.
Our study identified 10 comorbidities from medical claims in the 12-month period before the index date. The 10 comorbidities were developed based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Myocardial infarction, congestive heart failure, peripheral vascular diseases, cerebrovascular diseases, chronic pulmonary diseases, rheumatic diseases, diabetes mellitus, kidney diseases, and liver diseases were identified using similar ICD-9-CM codes, adopted to derive the Modified Charlson Comorbidity Index. 19 Since some studies reported that depression and bipolar disorder are associated with statin adherence and health care costs, 15,20 these 2 psychiatric conditions were also identified based on medical claims in a year prior to the index date. ICD-9-CM codes for identifying depression or bipolar disorders included 296.0 (bipolar disorder, single manic episode); 296.1 (manic affective disorder, recurrent episode) and 296.4-296.8 (bipolar disorders); 296.2 (major depression, single episode); 296.3 (major depressive affective disorder, recurrent); 300.4 (dysthymic disorder); and 311 (depressive disorder, not elsewhere classified).
21,22

Statistical Analysis
To evaluate associations between statin adherence level, health care costs, and utilization, study subjects were stratified into 8 groups based on statin MPR level and sample size: < 40%, 40%-59%, 60%-69%, 70%-79%, 80%-84%, 85%-89%, 90%-95%, and 96%-100%. Study subjects were also divided into 4 groups based on age in years: 18-44, 45-54, 55-59, and 60-64. Furthermore, based on the copayment per Rx fill, study subjects were also divided into 5 groups: ≤ $8, $9-$15, $16-$20, $21-$35, > $35. Variations in health care costs and ER visits across groups with different statin adherence levels were first analyzed using analysis of variance (ANOVA). Hospitalization and characteristics of groups with different statin adherence levels were compared using chi-square tests.
Multivariate regression models were developed to test 3 hypotheses. The first hypothesis was that higher statin adherence levels are associated with lower health care costs in a year after statin treatment is started. The second hypothesis was that higher statin adherence levels are associated with lower hospitalization rates, and the third hypothesis was that higher statin adherence levels are associated with fewer ER visits in a year after statin therapy is started.
A GLM model with gamma distribution and log link function was performed to evaluate the association between health care costs and statin adherence level. Another GLM model with Poisson distribution and log link function was performed to identify the association between ER visits and statin adherence level. Ratios of costs and ER visits, which were the exponential of the estimated regression parameters, were presented in the GLM models to help understand the associations between the statin MPR level, health care costs, and utilization. A logistic regression model was developed to examine whether statin adherence level was associated with hospitalization rates. All the statistical analyses in which the significance level was 0.05 were performed using SAS Enterprise Guide 4.2 (SAS, Cary, NC).
■■ Results
The research subjects for this study were 10,312 adult patients aged 18-64 years who were enrolled in a health plan for state government or public school employees for 12 months before and after the index date, with the first statin Rx fill date from
Patients who had at least 2 fills of statin medications in a year after an index date, the first filling date of statin from 2009-2010, and enrolled for a year after the index date N = 21,391
FIGURE 1
Study Sample Selection Flow Chart
Patients who were aged at least 18 years with complete demographic information N = 21,384
Patients who had at least 2 hyperlipidemia or diabetes diagnoses in a year prior to the index date N = 19,263
Patients who were aged 64 years or younger on the index date N = 15,067
Patients who enrolled for 1 year before the index date N = 13,924
Patients who had no cancer 1 year prior to the index date N = 13,286
Patients who did not have trauma 1 year prior to the index date N = 10,312
Patients who were not aged at least 18 years or some demographic information was missing were excluded N = 7
Patients who did not have at least 2 hyperlipidemia or diabetes diagnoses in a year prior to the index date were excluded N = 2,121
Patients who wered aged 65 years and over on the index date were excluded N = 4,196
Patients who did not enroll 1 year before the index date were excluded N = 1,143
Patients who were diagnosed with cancer 1 year prior to the index date were excluded N = 638
Patients who suffered from trauma 1 year prior to the index date were excluded N = 2,974 The mean age of the research subjects was 54.65 years. Of the total number of research subjects, 42.33% were male. The most common comorbidity identified, based on ICD-9-CM codes in medical claims of research subjects, was diabetes, and 28.20% of research subjects had the condition. Other comorbidities identified among research subjects included myocardial infarction (2.35%), congestive heart failure (3.75%), peripheral vascular diseases (3.53%), cerebrovascular diseases (4.30%), chronic pulmonary diseases (10.89%), kidney diseases (1.44%), rheumatic diseases (1.84%), liver diseases (1.95%), and depression or bipolar disorders (8.09%). The research subjects had about $18.36 in copay per Rx fill in a year after taking the first statin Rx fill from 2009-2010. Of total subjects, 59.40% lived in a metropolitan statistical area with more than 50,000 residents, and 18.75% lived in a micropolitan statistical area with the population between 10,000 and 50,000. Research subjects living in a rural area with less than 10,000 residents accounted for 21.85% in the study sample.
There were significant variations in health care costs and utilization among patient groups stratified using statin MPR in a year after taking the first statin Rx fill from 2009-2010. ANOVA tests showed that variations in Rx costs, statin Rx costs, and total health care costs were statistically significant among patient groups defined using statin MPR level: <40%, 40%-59%, 60%-69%, 70%-79%, 80%-84%, 85%-89%, 90%-95%, and 96%-100%. ER visits among the 8 statin MPR groups also varied significantly. Variations in medical costs among the 8 groups were not statistically significant. A chi-square test also did not indicate significant variation in hospitalization among the 8 patient groups (Table 1) .
Variations in patient characteristics among MPR groups were also analyzed. Chi-square tests showed that variations in age, gender, average Rx copay per fill, and residence area characteristics among the 8 patient groups were statistically significant ( Table 2 ). These tests further indicated that variations in the rates of rheumatic diseases and depression or bipolar disorder among the 8 groups were statistically significant as well. There were no significant variations in the rates of the following comorbidities among the 8 statin MPR groups: myocardial infarction, congestive heart failure, peripheral vascular diseases, cerebrovascular diseases, chronic pulmonary diseases, diabetes, kidney diseases, and liver diseases (Table 3) .
A GLM model with gamma distribution and log link function was developed to evaluate whether there was a negative association between the statin MPR level and health care costs. The GLM model of cost ratios for the statin MPR groups were 1.07 (40%-59%), 1.14 (60%-69%), 1.05 (70%-79%), 1.11 (80%-84%), 1.19 (85%-89%), 1.21 (90%-95%), and 1.19 (96%-100%), with regard to the reference group of statin MPR < 40%. All the cost ratios, except 70%-79%, were statistically significant compared with the reference group, suggesting those groups had higher health care costs than the group with the lowest statin MPR level (Table 4) . After controlling for all the other covariates, including age, sex, comorbidities, Rx copay per fill, and residence area characteristics, the estimated health care costs from the GLM model for each statin MPR group were $5,381.13 (< 40%), $5,764.94 (40%-59%), $6,102.96 (60%-69%), $5,705.85 (70%-79%), $6,088.08 (80%-84%), $6,545.03 (85%-89%), $6,593.91 (90%-95%), and $6,574.08 (96-100%). The GLM model did not indicate that higher statin MPR level was associated with lower health care costs.
A multivariate logistic regression model was performed to examine the association between statin MPR level and hospi- 
Health Care Costs and Utilization Among Statin MPR Groups
■■ Discussion
More clinical benefits and cost savings may result from improved statin adherence levels. Statin therapy is associated with significant reduction in cardiovascular events that account for high health care costs and death. [2] [3] [4] High statin adherence levels may help prevent or slow the progress of cardiovascular diseases and thus help lower health care costs in the long term. Health care utilization, including hospitalization and ER visits, may also be reduced among patients maintaining high statin adherence levels. These reduced rates of health care utilization may translate into lower overall health care costs. Studies report that high adherence levels are associated with a lower risk of cardiovascular disease, less hospitalization, and lower costs after 3-year follow-up. 23, 24 However, benefits gained from higher statin adherence levels may not achieve the goals of primary and secondary prevention of cardiovascular diseases in the short term. Therefore, cost savings may not be observed among patients with high statin adherence levels in the short term, such as in the 1-year period of this study. talization. After controlling for other covariates, almost all the odds ratios of statin MPR groups, except 70%-79%, were smaller than 1, but none of the odds ratios were statistically significant, suggesting there was no difference in the likelihood of hospitalization of the patient groups with higher statin MPR (Table 5) .
Another GLM based on Poisson distribution and log link function was developed to assess whether the statin MPR level was associated with the rate of ER visits in a year after patients took the first statin Rx fill from 2009-2010. After controlling all other covariates, the GLM model showed that ratios of ER visits among statin MPR groups were 0.66 (60%-69%), 0.64 (80%-84%), 0.72 (85%-89%), 0.65 (90%-95%), and 0.64 (96%-100%). All the ratios of ER visits for these groups were smaller than 1 and statistically significant, suggesting the groups had fewer ER visits than the reference group with statin MPR < 40%. Groups with statin MPR from 96%-100% had the lowest observed rate of ER visits, about 36% lower than the rate observed for the group with statin MPR < 40%. Ratios of the groups with statin MPR from 40%-59% and from 70%-79% also had ratios of ER visits smaller than 1, but both P values were larger than 0.05 ( 
CHF = congestive heart failure; CPD = chronic pulmonary diseases; CVD = cerebrovascular diseases; DB = depression or bipolar disorders; DM = diabetes mellitus; KD = kidney diseases; LD = liver diseases; MI = myocardial infarction; MPR = medication possession ratio; PVD = peripheral vascular diseases; RD = rheumatic diseases.
TABLE 3
Comorbidities Among Statin MPR Groups tions in health status among groups with different statin MPR levels. As a result, health care costs may be underestimated among the groups with low statin MPR levels but overestimated among the groups with very high statin MPR levels in our models. The confounding problem with disease severity may also help explain why our models did not show lower health care costs and hospitalization among patient groups with high statin MPR.
Low statin adherence is a serious issue that could potentially mitigate the treatment benefits. Whether higher statin adherence is associated with cost savings and lower health care utilization within a year of treatment is still questionable. Statin therapy may not achieve significant benefits if patients are not adherent to treatment. Increasing statin adherence levels may bring about more treatment benefits among patients on therapy. However, Disease severity is a significant confounding factor affecting both statin adherence level and health care costs and utilization. Patients with poor health status are more likely to be adherent to statin therapy and are also more likely to incur higher costs and utilization rates. 25 On the other hand, patients who feel healthy, especially those with asymptomatic conditions such as high cholesterol, may be less likely to refill statin Rx orders, maintain high statin adherence levels, and seek health care. Our results showed patients aged 55-64 years generally had statin MPR levels higher than 70%, but a much higher percentage of patients aged 18-54 years had statin MPR level < 40%. It is possible that patients with higher statin adherence levels may suffer serious disease that prompts them to comply more closely with prescribed statin therapy. Our multivariate regression models may not adjust sufficiently for varia- 
CHF = congestive heart failure; CI = confidence interval; CPD = chronic pulmonary diseases; CVD = cerebrovascular diseases; DB = depression or bipolar disorders; DM = diabetes mellitus; KD = kidney diseases; LD = liver diseases; MI = myocardial infarction; MPR = medication possession ratio; PVD = peripheral vascular diseases; RD = rheumatic diseases.
TABLE 4
Generalized Linear Model Predicting Health Care Costs
health plans and other payers are also concerned about whether increasing statin treatment costs and other costs can offset the benefit gains from higher statin adherence levels, which may be accomplished by interventions of disease or care management programs. Since low-cost generic statin medications are available in the market today, the costs associated with statin therapy are somewhat modest compared with other therapeutic categories without many generics available. This study showed the average statin Rx costs in a year were $355.78. The mean statin Rx costs of the group with the highest statin MPR from 95%-100% were only $449.86 in a year after the index date. The results may relieve the concern of significantly increasing statin Rx costs due to higher statin adherence levels, especially now that most of the products are available generically. New blood cholesterol treatment guidelines promote moderate-intensity statin therapy among patients with high risk of ASCVD, such as type 2 diabetes alone or high 10-year risk of cardiovascular disease. 8 With less concern about statin treatment costs, health plans and employers can redesign health benefits related to statin copay to help patients comply with the new guidelines to improve statin adherence.
Our study followed research subjects who had at least 2 fills of statin prescriptions for 1 year as recommended by the Utilization Review Accreditation Commission and The Centers for Medicare & Medicaid Services for medication adherence calculation. More evidence about the associations between statin adherence level, health care costs, and utilization is needed. with the index dates in late 2010 were computed based on claims data from 2010-2011. Health care inflation rates were low during the 3-year period, when the U.S. economy was in recession. Because of these low rates, health care inflation or benefit changes from 2009-2011 might slightly affect the estimation of health care costs among the study subjects. The impact of health care inflation on the estimation of health care costs among groups with different statin adherence levels appeared to be minimal. In addition, formal winsorizing of cost outliers was not performed. Excluding cancers and trauma in our study sample may help alleviate the impact of outliers on health care costs and utilization.
Variations in health benefits among patients may affect statin adherence level and choices of health care services, among patients with hyperlipidemia may be a reduction in cardiovascular events, which in turn may bring about lower health care utilization and costs in the long term. Further research is needed to evaluate the associations between statin adherence levels, the cost of cardiovascular care, and health care utilization over a longer treatment period.
Limitations
Health care costs and utilization may vary significantly from year to year and among patients. Health care costs in a year after the index date in this study were computed based on medical and Rx claims spanning from 2009-2011. Health care costs of some patients were computed using paid administrative medical claims data from [2009] [2010] 
TABLE 6
Generalized Linear Model Predicting ER Visits especially visits to physicians. There were only 2 health benefit options provided to the study subjects from 2009-2011. The major difference between the 2 health benefit options was the deductible. One option included a $1,000 deductible for outof-network health care for an individual policyholder ($2,000 for family policyholders). The other benefit option required a $1,500 deductible for in-network health care and $3,000 for out-of-network health care for an individual beneficiary ($3,000 and $5,000, respectively, for a family policyholder). The high-deductible option required 20% coinsurance for a visit to an in-network primary care physician or specialist, while the low-deductible option required $25 copayment without deductible for a visit to an in-network primary care doctor and $35 for an in-network specialist visit. Both options required a 40% coinsurance for a visit to an out-of-network primary care physician or specialist. Variations in health benefits between the 2 options may impact the statin treatment choice and health care costs among the study subjects. Since all the study subjects were state government or public school employees residing within a single state, the impact of health benefit design on statin adherence level and health care services may not be significant.
Medical data of research subjects in this study were obtained from a health benefit plan of state government and public school employees. The raw medical claims files incurred in 3 major health care systems associated with this plan may contain adjustments, reversals, or denials that may not be properly reflected in the resulting data. The unadjusted medical claims may affect the calculation of medical costs and utilization in this study. However, since medical costs and health care utilization were identified based on the "from" date but not the "paid" date, the impact of unadjusted medical claims on calculating medical costs and health care utilization may not be significant.
Financial benefits of statin treatment derive from lowering cardiovascular disease-related morbidities and mortality, which often constitute a large portion of health care costs and utilization. This study examined the relationships between the statin adherence level and overall health care costs and utilization. It is not known to what extent cardiovascular disease-related costs and utilization, which are associated with the statin adherence level, account for the overall health care costs and utilization among patients on statin treatment in this study.
This study was performed based on extracts of medical and pharmacy data, derived from their respective claims and adjudication environments, which are designed for administrative purposes. As an observational study, this study could not collect additional variables to reduce the impact of confounding factors, known or unknown. Some important confounding factors affecting the statin adherence level, health care costs, and utilization may not be observed from claims data. Unobserved or untested confounders in this study may bias estimates of the associations between statin adherence level, health care costs, and utilization, such as the possible occurrence of myalgia or rhabdomyolysis, which were not examined. Some patients' access to physicians, which significantly affects health care costs and utilization, may be a barrier to receiving prescribed medications, including statins. Variations in patient characteristics, such as race and income, may also impact statin adherence level and health care costs and utilization. Since the study sample came from a health plan of state government and public school employees in a midwestern state, the results may not be generalized to other populations.
Statin MPR in this study was measured from the earliest date in a time period when patients filled a statin Rx, but not necessarily the date when patients first initiated statin therapy. Possibly some patients were not naïve to therapy. There are 2 main reasons why we took this approach to measure statin adherence level and selected the study sample. Interventions improving statin adherence often target all the patients who may benefit from cholesterol-lowering treatment, not only those initiating statin therapy. Evidence from patients who just start statin treatment may not be generalizable to other patients, who may have already taken statin for some time and whose characteristics may differ significantly from patients initiating statin treatment. Study subjects in 1 statin MPR group may have taken statin for some time and maintain higher statin adherence levels prior to the index date, when they filled the first statin Rx from 2009-2010. Estimates of associations between statin MPR level, health care costs, and utilization may be biased among those patients. Another reason for including patients who were not naÏve to statin therapy was because of concern about the study sample size, which had to be large enough to stratify study subjects into multiple groups.
■■ Conclusions
Our results suggest that high statin adherence levels are associated with fewer ER visits among beneficiaries under the age of 65 who have an indication for statin therapy based on guidelines previous to the new ACC/AHA recommendations after 1 year of therapy. However, it is inconclusive whether higher statin adherence levels are associated with lower overall health care costs within 1 year after statin therapy is observed. This research adds to the body of existing evidence that has focused on higher statin adherence and associations with all-cause health care costs and medical utilization. Further research is needed to evaluate the associations between statin adherence levels, the cost of cardiovascular care, and cardiovascularrelated utilization over a longer time period, especially among high-risk populations based on the new ACC/AHA criteria.
